MAPT and Cognitive impairment: Therefore, we measured plasma concentrations of p-tau217 and p-tau181, as well as the corresponding unphosphorylated tau peptides, 212-221 (Tau212-221) and 181-190 (Tau181-190) in patients with mild cognitive impairment in a first cohort.